No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
TNDM240719C42500
- 0.95
- -0.30-24.00%
15min DelayClose Jun 28 16:00 ET
1.95High0.95Low
1.93Open1.25Pre Close79 Volume130 Open Interest42.50Strike Price12.94KTurnover53.88%IV7.84%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier18DDays to Expiry0.95Extrinsic Value100Contract SizeAmericanOptions Type0.3631Delta0.0757Gamma35.03Leverage Ratio-0.0513Theta0.0070Rho12.72Eff Leverage0.0345Vega
Intraday
- 5D
- Daily
News
Wells Fargo Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $50
Is weight loss medicine or stock market bomb? Eli Lilly and Co's new drug tirzepatide caused a sharp drop in sleep device stocks.
The recent clinical trial results of the new weight loss drug tirzepatide have not only caused a sensation in the medical community, but also stirred up waves in the stock market.
Tandem Diabetes, DexCom See Weakness Following ADA Conference
Lake Street Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $75
TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $45
Tandem Mobi Improves Quality of Life for People Living With Type 1 Diabetes in New Data Shared at American Diabetes Association Scientific Sessions
Comments
$Tandem Diabetes Care(TNDM.US$
Just check call options. they are expensive
However, stock price moves only 5-10% with no news. Something is going on behind the scene?!
Just check call options. they are expensive
However, stock price moves only 5-10% with no news. Something is going on behind the scene?!
1
Despite losses and negative cash flow, the company's US$178.2m balance sheet allows for at least two years of growth spending. However, the stock is seen as risky due to these financial conditions.
1
Tandem Diabetes Care's share price rise sparks hope, but turnarounds can be risky. The gap between revenue and share price growth could warrant further investigation. Last year's performance suggests unresolved issues, as it underperformed the annualised 10% loss over the past five years.
The stock is undervalued, indicating a potential buy opportunity. The company's positive future outlook and expected earnings increase aren't fully reflected in the current share price. Consider the company's financial health as well.
Despite the good rate of top-line growth at Tandem Diabetes Care, the severe share price drop indicates the company's losses might be larger than expected. Given the stock's past poor performance, there may be unresolved challenges the company is facing.
Read more